Loading...
XHKG2289
Market cap125mUSD
Dec 19, Last price  
9.00HKD
Name

Charmacy Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XHKG:2289 chart
P/E
17.78
P/S
0.21
EPS
0.48
Div Yield, %
7.77%
Shrs. gr., 5y
—
Rev. gr., 5y
2.27%
Revenues
4.40b
+5.47%
2,401,231,0003,014,059,0003,397,133,0003,669,781,0914,095,835,4493,935,245,9763,492,782,9113,991,710,5233,793,617,7194,175,279,0394,403,633,478
Net income
51m
-43.25%
22,219,00036,445,00026,359,00059,348,00044,759,91145,432,94940,153,35540,555,96523,153,06090,471,95651,344,725
CFO
0k
-100.00%
45,104,000-14,826,000193,670,000-101,551,472-32,960,13849,151,3964,018,929131,076,849-19,543,39344,050,3010
Dividend
May 22, 20240.32977 HKD/sh
Earnings
May 20, 2025

Profile

Charmacy Pharmaceutical Co., Ltd. engages in the trading of pharmaceutical products in the People's Republic of China. The company offers western medicines, Chinese patent medicines, healthcare products, and related consulting services to downstream distributors and terminal chemists. It also operates Charmacy e-Medicine, a B2B e-commerce platform to place orders online and make inquiries and payments. The company was formerly known as Chuangmei Pharmaceutical Co., Ltd. and changed its name to Charmacy Pharmaceutical Co., Ltd. in July 2016. Charmacy Pharmaceutical Co., Ltd. was incorporated in 1984 and is headquartered in Shantou, the People's Republic of China.
URL
https://www.chmyy.com/
IPO date
Dec 14, 2015
Employees
817
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
4,403,633
5.47%
4,175,279
10.06%
3,793,618
-4.96%
Cost of revenue
4,281,693
4,069,237
3,711,352
Unusual Expense (Income)
NOPBT
121,940
106,042
82,266
NOPBT Margin
2.77%
2.54%
2.17%
Operating Taxes
16,075
31,673
9,828
Tax Rate
13.18%
29.87%
11.95%
NOPAT
105,865
74,369
72,438
Net income
51,345
-43.25%
90,472
290.76%
23,153
-42.91%
Dividends
(75,500)
Dividend yield
5.39%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,531,069
1,390,027
1,512,566
Long-term debt
67,368
31,510
102,331
Deferred revenue
305
Other long-term liabilities
601
1
(708)
Net debt
953,680
542,993
483,808
Cash flow
Cash from operating activities
44,050
(19,543)
CAPEX
(40,849)
(8,589)
(25,040)
Cash from investing activities
39,337
71,762
(24,402)
Cash from financing activities
101,262
(191,212)
74,401
FCF
28,986
(14,161)
142,739
Balance
Cash
644,756
503,807
641,756
Long term investments
374,737
489,334
Excess cash
424,575
669,780
941,409
Stockholders' equity
319,805
316,480
226,100
Invested Capital
1,840,062
1,589,628
1,845,671
ROIC
6.17%
4.33%
3.91%
ROCE
5.65%
5.56%
3.97%
EV
Common stock shares outstanding
108,003
107,994
107,990
Price
12.96
90.59%
6.80
21.86%
5.58
 
Market cap
1,399,722
90.60%
734,361
21.87%
602,584
 
EV
2,353,402
1,277,354
1,086,392
EBITDA
148,410
134,879
114,301
EV/EBITDA
15.86
9.47
9.50
Interest
40,790
35,073
41,517
Interest/NOPBT
33.45%
33.07%
50.47%